Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?

Viracta Therapeutics (NASDAQ:VIRX) stock is heading higher on Wednesday after the clinical-stage precision oncology company released its Q2 earnings report. The first bit of news boosting VIRX stock higher is its diluted earnings per share of -25 cents. That's better than the -37 cents per share Wall Street was predicting. It's also an improvement over the company's EPS of -32 cents from the same period of the year prior. Viracta Therapeutics notes that the improvement in its EPS comes from a $5 million of ...